RCPT 109.24 Receptos Inc $RCPT Hit a 52 week high of 112.70

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
RCPT 109.24 Receptos Inc $RCPT Hit a 52 week high of 112.70 Currently at 109.24 -1.28 -1.16% With a day low of 108.70 and a total volume of 794,000.

RCPT Receptos Inc Recent Headline News

Receptos to Present at Credit Suisse Healthcare Conference
GlobeNewswire - Thu Nov 06, 3:03PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that Faheem Hasnain, its President and Chief Executive Officer, will be presenting at the Credit Suisse Healthcare Conference at The Biltmore Hotel in Phoenix, Arizona. The presentation is scheduled for Wednesday, November 12 at 8:30am. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
RCPT: 109.24 (-1.28)

Receptos posts 3Q loss
Automated Insights - Tue Nov 04, 7:19AM CST
SAN DIEGO (AP) _ Receptos Inc. (RCPT) on Tuesday reported a loss of $32.2 million in its third quarter.
RCPT: 109.24 (-1.28)

Receptos Provides Development Updates and Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 04, 6:00AM CST
- Recent positive Phase 2 induction results for TOUCHSTONE trial of RPC1063 in ulcerative colitis (UC) support initiation of broad program in inflammatory bowel disease -
RCPT: 109.24 (-1.28)

Receptos to Present at Nomura BioPharma Conference
GlobeNewswire - Mon Nov 03, 3:01PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that Faheem Hasnain, its President and Chief Executive Officer, will be presenting at the Nomura BioPharma Conference at the Mandarin Oriental Hotel in Boston. The presentation is scheduled for Thursday, November 6 at 2:15pm Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
RCPT: 109.24 (-1.28)

Clinical Trial Results, Product Approval Letter, Financial Results, and Upcoming Event - Research Reports on Receptos, Wright, United Therapeutics, Abbott and CareFusion
PR Newswire - Fri Oct 31, 7:40AM CDT
Today, Analysts Review released its research reports regarding Receptos Inc. (NASDAQ: RCPT), Wright Medical Group Inc. (NASDAQ: WMGI), United Therapeutics Corporation (NASDAQ: UTHR), Abbott Laboratories (NYSE: ABT) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7594-100free.
ABT: 43.37 (-0.32), WMGI: 27.95 (-0.49), CFN: 57.28 (-0.16), UTHR: 124.21 (-1.12), RCPT: 109.24 (-1.28), WMGIZ: 4.31 (-0.04)

Receptos to Hold Third Quarter 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Wed Oct 29, 3:12PM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will announce financial results for the third quarter ended September 30, 2014 on Tuesday, November 4 before the markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time (5:00 a.m. Pacific time).
RCPT: 109.24 (-1.28)

Receptos (RCPT) Worth Watching: Stock Moves Up 41.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:39AM CDT
Receptos, Inc. (RCPT) was a big mover last session, as its shares rose over 41% on the day.
LCI: 50.17 (-0.82), PTLA: 27.39 (-0.33), RCPT: 109.24 (-1.28), IG: 9.45 (-0.25)

Nasdaq stocks posting largest percentage increases
AP - Tue Oct 28, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
VDSI: 26.63 (+0.14), ECHO: 27.33 (-0.21), LAYN: 7.52 (+0.26), NVAX: 4.95 (-0.20), SCYX: 9.00 (+0.10), RCPT: 109.24 (-1.28), TRNX: 25.50 (-0.09), IDTI: 17.73 (-0.07), SANM: 25.60 (-0.23)

Twitter and Amgen are big market movers
AP - Tue Oct 28, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 6.39 (-0.14), KSS: 57.22 (+0.41), MU: 33.01 (-0.34), PFE: 29.92 (-0.12), HAL: 53.86 (+0.69), AMGN: 160.25 (-0.10), NQ: 7.18 (+0.20), RGC: 22.15 (-0.07), MS: 35.66 (+0.35), MSG: 75.15 (+0.27), NVAX: 4.95 (-0.20), CQB: 14.43 (+0.01), SRPT: 16.12 (-0.14), RCPT: 109.24 (-1.28), TWTR: 40.31 (-0.53), PTIE: 1.71 (-0.11)

Health Care Stocks On The Rise With Help From 3 Stocks
at The Street - Tue Oct 28, 12:04PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
AMGN: 160.25 (-0.10), RCPT: 109.24 (-1.28), NVS: 91.76 (-0.27)

Receptos Soars After Lead Drug Racks Up Another Win
at Investor's Business Daily - Tue Oct 28, 10:46AM CDT
Receptos (RCPT) stock jumped more than 47% to a new high above 99 in morning trading on the stock market today, and the company got multiple price-target increases after its bowel-disease drug succeeded in a midstage trial. Receptos announced late...
JNJ: 108.20 (-0.81), RCPT: 109.24 (-1.28), ABBV: 61.50 (-1.21)

Stock Futures Positive, Steady; Vasco Rockets, Twitter Fades
at Investor's Business Daily - Tue Oct 28, 8:01AM CDT
Stock futures rolled up moderate gains ahead of Tuesday's open, as investors geared up for a session with many moving parts. Dow futures were steady, trading 73.1 points above fair market value. Nasdaq 100 futures were up a strong 19.4 points, and...
WHR: 175.81 (+0.97), VDSI: 26.63 (+0.14), RCPT: 109.24 (-1.28), BP: 42.06 (+0.19), TWTR: 40.31 (-0.53), AET: 82.29 (-2.41)

RECEPTOS
at Investor's Business Daily - Mon Oct 27, 5:48PM CDT
RECEPTOS (RCPT), a biotech, reported positive phase 2 trial results for its RPC1063 treatment for ulcerative colitis. Shares shot up 25.1% to 85.02.
RCPT: 109.24 (-1.28)

Receptos Reports Positive Phase 2 Results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis
GlobeNewswire - Mon Oct 27, 3:01PM CDT
- Study met primary efficacy and all secondary endpoints with statistical significance for patients on 1 mg dose after 8 weeks of treatment -
RCPT: 109.24 (-1.28)

Surprising Stocks That Performed Best for Billionaires in 2014
at The Street - Mon Oct 27, 7:48AM CDT
See the stocks that have performed the best for 19 billionaires who made their money investing.
BDSI: 15.50 (-0.34), ATHL: 58.34 (+0.11), VIPS: 23.34 (-0.04), ARII: 66.28 (+0.15), SBAC: 114.62 (+2.97), BIOF: 7.28 (+0.01), BKW: 32.60 (-0.72), LUV: 38.24 (+0.30), HCA: 65.75 (-3.22), LPDX: 5.23 (+0.01), DTV: 87.40 (-0.08), RCPT: 109.24 (-1.28), WMB: 55.38 (+0.67), BRK.B: 143.61 (+0.32), BRK.A: 214,970.00 (+170.00), SBGL: 7.16 (+0.24), AN: 57.59 (-0.26)

Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis
GlobeNewswire - Fri Oct 03, 6:59AM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that the first patient has been treated in a Phase 2 trial of RPC4046, Receptos' development candidate for eosinophilic esophagitis (EoE). RPC4046 is a humanized monoclonal antibody directed against interleukin-13 (IL-13), a target which has been validated in other related allergic indications.
RCPT: 109.24 (-1.28)

The 5 Best Biotech Stocks in 2014...so far
Todd Campbell, The Motley Fool - Motley Fool - Fri Sep 26, 7:35AM CDT
Since the quarter is wrapping up and investors are considering their game plan heading into year-end, let's look at biotech's biggest winners for the year, why they've rallied, and whether they make sense for your portfolio . Specifically, let's...
GILD: 106.45 (-0.49), ACHN: 10.11 (-0.15), RCPT: 109.24 (-1.28), PTCT: 40.24 (-1.93), ICPT: 172.59 (-74.39), PBYI: 236.89 (-3.28)

Critical Alerts For FuelCell Energy, Receptos Inc., HD Supply Holdings Inc., Westport Innovations and Organovo Released By InvestorsObserver
PR Newswire - Thu Sep 11, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FCEL, RCPT, HDS, WPRT and ONVO.
WPRT: 6.06 (+0.38), FCEL: 2.11 (+0.09), ONVO: 6.97 (+0.13), HDS: 29.01 (-0.32), RCPT: 109.24 (-1.28)

Market Maker Surveillance Report. NPSP, CYTK, JDSU, INVT, MNDL, RCPT, Winning Stocks With Lowest Price Friction For Wednesday, September 10th 2014
M2 - Thu Sep 11, 4:12AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4911 companies with "abnormal" market making, 2481 companies with positive Friction Factors and 2383 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Wednesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. NPS Pharmaceuticals Inc (NASDAQ:NPSP), Cytokinetics Inc (NASDAQ:CYTK), JDS UNIPHASE CORPORATION (NASDAQ:JDSU), INVESTAMERICA INC (OTC:INVT), Mandalay Digital Group Inc (OTC:MNDL), (NASDAQ:RCPT). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
CYTK: 4.10 (-0.15), INVT: 1.30 (+0.02), RCPT: 109.24 (-1.28), JDSU: 13.63 (+0.21), NPSP: 27.49 (+0.15), MNDL: 3.63 (+0.30)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innventure Faces Legal Scrutiny Over DarkNX Debacle

Updated Category News Views 70

Innventure’s Market Tumult: Unraveling the Drama Talk about a mess. Innventure Inc. (NASDAQ: INV) investors are likely feeling a sting sharper than a bee that's lost its hive after a painful 55% stock crash back in August 2026. The culprit? A scuttled project involving a shadowy partner, DarkNX, and a lot of questions about who knew what and when. A Puzzling...

Continue Reading
Minesto Teams Up to Unlock Tidal Power in Maldives

Updated Category News Views 154

The world of ocean energy just got a jolt from an unlikely corner. Minesto, the ocean energy whiz, and Morteza Capital, a savvy investment force entrenched in the Maldives, are shaking hands to usher tidal energy into this paradise. Tidal Waves Meet Tourism When you're talking about the Maldives, you're talking about two main things: pristine tropical getaways and a whole...

Continue Reading
Bank of America Faces Legal Battle Over Compliance Failures

Updated Category News Views 39

Another Day, Another Lawsuit Just when you thought the financial waters were calm, there's a storm brewing for Bank of America Corp. (NYSE: BAC). They've been slapped with a securities class action lawsuit that screams all kinds of regulatory and compliance failures. You’d think with all that cash flow, BAC could afford to run a tight ship. But apparently, they decided...

Continue Reading
Veterans, Lawmakers Forge Paths in Spokane Forum

Updated Category News Views 0

Spokane Forum Sparks Action for Veterans' Policies Gonzaga University turned into a powerhouse of dialogue and determination as the Wounded Warrior Project (WWP) gathered over 145 veterans, elected officials, and advocate groups to hash out critical policy priorities. We're talking high-stakes discussions with real consequences, not just some feel-good meet-up. A...

Continue Reading
Tennessee's Bold Lung Cancer Trial Signals Innovation

Updated Category News Views 347

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...

Continue Reading
Medline's Decade-Long WRAP Partnership: More Than Labels

Updated Category News Views 144

A Decade of Trust and Responsibility Here we go, folks—Medline is toasting 10 years with WRAP, and this ain't just fluffy PR spin. When two big players like these lock arms over responsible manufacturing, it's a signal worth paying attention to, and not just for the ethics alone. Production practices that prioritize transparency and worker rights have ramifications...

Continue Reading
Reimagining Water: A Crisis and a Call to Action

Updated Category News Views 121

Time for a Change The head of the World Water Council, Loïc Fauchon, didn't mince words at the 9th Cairo Water Week. He proclaimed the old methods of water management are sinking under a flood of modern challenges. Toss in climate upheavals, ballooning cities, and unpredictable diets, and you've got yourself a swirling mess that traditional strategies just can’t mop...

Continue Reading
UFP Industries Fortifies Gulf Coast with $27M Buy

Updated Category News Views 65

UFP Industries Makes a Strategic Move Folks, it looks like UFP Industries (NASDAQ: UFPI) is making some solid moves down in the Gulf Coast, and they're shelling out $27 million to do it. This time, they've got their eyes on Apache Products, dba Acme Skid, a company that's been doing the heavy lifting in the pallet manufacturing space in Silsbee, Texas. Apparently, these...

Continue Reading
CSQR Faces Scrutiny Over Cash Flow Discrepancies

Updated Category News Views 40

Dalrymple's Short Report Shakes Csquare's Core Csquare, Inc. (NYSE: CSQR) is reeling from a one-two punch: a damning short report by Dalrymple Finance and an 11.8% share tumble. The timing of this financial body blow, coinciding with Csquare's discordant cash flow claims, could mark the beginning of a long battle for investor trust. This ain't the first time the markets...

Continue Reading
OncoHost's Research Links TKI Sensitivity to Biology

Updated Category News Views 121

Cracking the Code on TKI Sensitivity When it comes to medicine, sometimes the trickiest part is knowing which button to push—especially in the high-stakes world of metastatic renal cell carcinoma (mRCC). OncoHost just dropped a bombshell at the ESMO 2026 Congress about their new plasma proteomics model that lets us peer into what makes some patients click with Tyrosine...

Continue Reading

Top 5 Most Recently Viewed Articles

Fosun International's Steady Growth: A Look at 2025 Results

Updated Category News Views 224

Fosun International Reports Impressive Interim Results Fosun International Limited (HKEX stock code: 00656, "Fosun International") has announced robust interim results, highlighting sustained growth across its core businesses. The total revenue reached RMB87.28 billion, with notable strides in global operations and technological innovation. Key Financial Highlights The...

Continue Reading
Flare Therapeutics Shines Light on FX-909 Phase 1A Breakthrough

Updated Category News Views 159

Flare Therapeutics Presents Groundbreaking Phase 1A Results Flare Therapeutics Inc. has recently made headlines with their announcement regarding the presentation of clinical data for FX-909, a promising therapeutic candidate in the fight against cancer. This upcoming presentation will take place at an esteemed conference focusing on molecular targets and cancer...

Continue Reading
RIV Capital Expands Adult-Use Cannabis Sales in Kingston

Updated Category News Views 71

RIV Capital Expands Adult-Use Cannabis Sales in Kingston RIV Capital Inc. (CSE: RIV) is making strides in the cannabis market with its recent announcement regarding the launch of adult-use sales at the Etain dispensary. This development marks a significant milestone in the company’s efforts to provide both medical and recreational cannabis to consumers. Location and...

Continue Reading
Water.org's Innovative Strategies for Fighting Water Scarcity

Updated Category News Views 336

Water.org's Commitment to Addressing Water Issues Water.org is embarking on an ambitious journey in FY25, focusing on crucial strategies to tackle the world's water and sanitation crisis. Building on substantial accomplishments from FY24, the organization mobilized $965 million to provide safe water and sanitation to over 10.2 million people. Their relentless efforts to...

Continue Reading
Dexcom's Promising Revenue Projections for 2025 Ignite Interest

Updated Category News Views 484

Dexcom's Positive Revenue Outlook Shares of Dexcom (NASDAQ: DXCM), a leading company in medical devices focused on glucose monitoring systems, have experienced a notable uptick of 5%. This surge in stock value comes on the heels of their announcement regarding the anticipated revenue for 2025. Strong Fourth-Quarter Performance In an encouraging sign for investors,...

Continue Reading